Decreased PGC1β expression results in disrupted human erythroid differentiation, impaired hemoglobinization and cell cycle exit

Taha Sen, Jun Chen & Sofie Singbrant*

Production of red blood cells relies on proper mitochondrial function, both for their increased energy demands during differentiation and for proper heme and iron homeostasis. Mutations in genes regulating mitochondrial function have been reported in patients with anemia, yet their pathophysiological role often remains unclear. PGC1β is a critical coactivator of mitochondrial biogenesis, with increased expression during terminal erythroid differentiation. The role of PGC1β has however mainly been studied in skeletal muscle, adipose and hepatic tissues, and its function in erythropoiesis remains largely unknown. Here we show that perturbed PGC1β expression in human hematopoietic stem/progenitor cells from both bone marrow and cord blood results in impaired formation of early erythroid progenitors and delayed terminal erythroid differentiation in vitro, with accumulations of polychromatic erythroblasts, similar to MDS-related refractory anemia. Reduced levels of PGC1β resulted in deregulated expression of iron, heme and globin related genes in polychromatic erythroblasts, and reduced hemoglobin content in the more mature bone marrow derived reticulocytes. Furthermore, PGC1β knock-down resulted in disturbed cell cycle exit with accumulation of erythroblasts in S-phase and enhanced expression of G1-S regulating genes, with smaller reticulocytes as a result. Taken together, we demonstrate that PGC1β is directly involved in production of hemoglobin and regulation of G1-S transition and is ultimately required for proper terminal erythroid differentiation.

Mammalian red blood cells (RBC) are the most abundant cells in the body, with the primary function to transport oxygen and clear distal tissues of carbon dioxide. RBCs have a finite lifetime of approximately 120 days and require continuous production through erythropoiesis, a step-wise process requiring delicate coordination of intrinsic and extrinsic regulators. Imbalanced coordination drives the pathogenesis of various anemia related disorders. During erythropoiesis pluripotent hematopoietic stem cells differentiate through a series of tightly regulated intermediate steps into mature RBCs. The first erythroid committed colony forming progenitors BFU-Es and the subsequent CFU-Es have activated expression of the receptor for erythropoietin (EPO), the main hormone responsible for maintenance and proliferation of erythroid committed progenitors during definitive erythropoiesis. During the subsequent terminal differentiation erythroblasts undergo stepwise maturation, becoming smaller and increasingly hemoglobinized with each division, condense their nuclei, autophagocytize mitochondria and other organelles, and finally exit cell cycle and extrude their nuclei.

Mitochondrial biogenesis is enhanced through post-transcriptional modifications in human erythropoiesis, and recent advances have implicated that mitochondrial dysfunction leads to impaired erythropoiesis, indicating that proper mitochondrial function is critical for erythroid development. Differentiating erythroblasts have increased energy demands, which mitochondria supply by ramping up oxidative phosphorylation (OXPHOS). Additionally, mitochondria are responsible for heme and iron metabolism, two components critical for proper function of erythrocytes. The PPAR-gamma coactivator-1 (PGC-1) family of transcriptional coactivators have been shown to regulate mitochondrial capacity and energy metabolism through various nuclear receptors and...
recruitment of protein complexes to specific DNA sequences\(^\text{16}\). They are preferentially expressed in tissues with high OXPHOS needs, and the first member, PGC1α was identified in brown adipose tissue where it was shown to regulate mitochondrial biogenesis\(^\text{17,18}\). The PGC1α homologs, PGC1β and PGC-1-related coactivator (PRC), exert similar downstream effects\(^\text{19,20}\). However, due to tissue-specific expression patterns, the various PGC1 coactivators have distinct physiological roles dependent on the availability of the numerous nuclear receptors through which cellular metabolism is controlled\(^\text{16}\).

Pgc1β display increased expression during terminal erythroid differentiation\(^\text{11}\). However, its function has mainly been studied in adipocytes, hepatic-, cardiac and skeletal tissues\(^\text{19,22-25}\), while the role of PGC-1β in erythropoiesis remains largely unknown. The only study to date directly evaluating the role of PGC-1 coactivators during RBC development demonstrates that compound deletion of the related Pgc1a and Pgc1β during embryonic development in mouse results in anemia due to deregulation of globin genes\(^\text{26}\). Furthermore, we recently demonstrated that perturbed PGC1β expression in response to pRb-deletion in mice results in a developmental block during terminal erythropoiesis and anemia reminiscent of that reported in Myelodysplastic syndrome (MDS)\(^\text{21,27}\). Importantly, the MDS-like anemia could be rescued by enhanced PPAR-signaling, either through PGC1β over-expression or Bezafibrate treatment\(^\text{28}\), indicating that PGC1β plays a functional role in the anemic phenotype. Notably, PGC1β is haplo-insufficient in the chromosome 5q deletion subtype of MDS (del(5q) MDS)\(^\text{29}\) and deregulation of core mitochondrial pathways and acquired mtDNA mutations have been reported in MDS-patients with anemia\(^\text{30}\), generally in genes related to iron and heme homeostasis\(^\text{12,20,31}\). However, the role of PGC1β in regulation of human erythropoiesis is yet to be determined.

To decipher the role of PGC1β in human erythropoiesis, PGC1β was knocked down in bone marrow derived CD34+ hematopoietic stem/progenitor cells and investigated for its effects during erythroid differentiation. Here we show that PGC1β is required for proper human erythroid development, and that perturbed expression results in delayed differentiation in vitro, with accumulations of polychromatic erythroblasts similar to what is seen in MDS-related refractory anemia. Transcriptional and functional analysis revealed that reduced levels of PGC1β resulted in perturbed hemoglobin production, as well as disturbed cell cycle exit with smaller reticulocytes as a result.

Results. Pgc1 coactivators have been indicated to play a role during murine erythropoiesis\(^\text{26}\), while their function in human erythropoiesis remains unknown. To further decipher the role of PGC1β during human erythroid development, we reduced the PGC1β expression in human CD34+ bone marrow (BM) and cord blood (CB) progenitors using lentiviral knock-down with two different shRNAs (sh3, sh5) to reduce the risk of off-target effects (Fig. 1A), and investigated its effects during erythroid differentiation in vitro. High initial transduction efficiency, on average 65%, was achieved with both vectors (data not shown), with sh3 consequently resulting in more efficient knock-down of PGC1β expression than sh5, averaging 48% and 26% respectively for BM (Fig. 1B, n = 4 biological replicates times 3 and 2 separate transductions for sh3 and sh5 respectively), and 55% and 25% respectively for CB (Fig. 1C). PGC1β knock-down efficiency was further assessed at the protein level in CB derived CD34+ cells. Surprisingly, sh5 with less efficient mRNA knock-down at the transcriptional level displayed a more effective reduction at the protein level (Fig. 1D, full blot in Fig. S1). Transduced (GFP+) CD34+ BM and CB cells were sorted and the effects of perturbed PGC1β expression were analyzed using a three-phase culture system that over 21 days effectively recapitulates human erythroid development from hematopoietic stem/progenitor cells to reticulocytes, including all intermediate erythroid precursors (Fig. 1E, modified from Hu et al. 2013)\(^\text{32}\), with some differences in kinetics in proliferation and differentiation between CD34+ progenitors derived from fetal and adult sources\(^\text{33}\).

Decreased expression of PGC1β results in perturbed formation of early erythroid progenitors and delayed terminal differentiation. To investigate the role of PGC1β during early erythroid development, transduced CD34+ BM stem/progenitor cells were plated in methyl cellulose and analyzed for formation of erythroid colony forming units (CFU-Es) on day 14. Decreased expression of PGC1β severely affected the capacity of multipotent CD34+ progenitors to form CFU-Es, with a striking 8.8 and 25.5-fold reduced CFU-E-formation for sh3 and sh5 respectively (Fig. 2A). To further understand the importance of PGC1β during terminal erythroid differentiation, we took advantage of the pan-erythroid surface marker Glycophorin A/CD235a (GPA) in combination with differential expression of surface markers Cd49d and Band3\(^\text{34}\), and increased hemoglobin availability naturally occurring during stepwise erythroid maturation (Fig. 2B). Flowcytometric analysis of transduced, cultured BM cells on day 10 (GPA+ cell emergence), day 14 (early erythroid differentiation), day 18 and day 21 (terminal erythroid differentiation) revealed that decreased expression of PGC1β resulted in a significant reduction in the overall formation of erythroid cells (GPA+) on day 10 and day 14, which was normalized by day 18 and day 21 (Fig. 2C,D).

Further fractionation of GPA+ erythroid progenitors demonstrated that reduced expression of PGC1β resulted in delayed erythroid maturation, with increasing accumulation of basophilic/polychromatic erythroblasts (Cd49d+/Band3−) and impaired formation of more mature polychromatic/orthochromatic erythroblasts (Cd49d+/Band3+) on day 14 and day 18 of culture respectively (Fig. 2C,D). Erythroid differentiation was close to normalized on day 21, when the majority of cells in the culture had reached final maturation (orthochromatic erythroblasts/Reticulocytes, Cd49d-/Band3+). Terminal erythroid maturation was further analyzed morphologically, allowing more detailed fractionation. Morphological scoring demonstrated that the surface markers Cd49d and Band3 mark a continuum of differentiating erythroblasts. Furthermore, the intensity of Band3 doesn’t increase substantially between day 14 and day 18, although the cells contained in the Cd49d+/Band3− compartment are significantly more mature on d18 (polychromatic erythroblasts) than on day 14 (basophilic). In accordance with the flowcytometric results, scoring of cells stained with Giemsa together with hemoglobin-marking
3,3′-Diaminobenzidine (DAB) (Fig. 2E) demonstrated a delay in maturation with accumulations of basophilic erythroblasts (II) on day 14, and at the polychromatic erythroblast stage (III) on day 18 (Fig. 2F). Again, the formation of more mature orthochromatic erythroblasts and reticulocytes (IV, V) was close to normalized by day 21 (Fig. 2F). The DAB-Giemsa quantification was not possible on day 10, since GPA+ and GPA− progenitors could not be distinguished morphologically.

Differentiation from CD34+ cells to mature erythroid progenitors occurs faster in CB compared to BM. As a result, analyses for CB were done on day 10, 14 and 16, with day 16 corresponding to between day 18 and day 21 of BM differentiation. Knock-down of PGC1β in CB derived CD34+ cells resulted in a developmental delay that was even more pronounced compared to BM, with remaining significantly reduced levels of Cd49d−/Band3+ progenitors on day 16 (Fig. 3A, B). The more pronounced reduction of formed GPA+ cells during early erythropoiesis using sh5 as compared to sh3 can likely be attributed to the lower PGC1β protein levels caused by sh5-mediated knock-down. Analysis of enucleation using the nucleic acid stain Syto62 demonstrated that knock-down of PGC1β also resulted in significantly reduced enucleation in mature GPA+ cells compared to control (Fig. 3C).

In conclusion, reduced expression of PGC1β results in perturbed formation of early erythroid progenitors and impaired terminal erythroid differentiation with an accumulation of polychromatic erythroblasts and a subsequent reduction of more mature erythroblasts, a phenotype that is reminiscent of the refractory anemia seen in many MDS patients27 and the MDS-like anemia we have previously reported on in mouse21.

**PGC1β knock-down results in deregulated hemoglobinization of erythroid progenitors.** The functional role of the mitochondrial coactivator PGC1β in erythropoiesis remains largely unknown. However,
Figure 2. Decreased expression of PGC1β results in perturbed formation of early erythroid progenitors and delayed terminal differentiation in BM. (A) Representative pictures (left) and quantification (right) of CFU-E colonies at day 14 (n = SCR:4, Sh3:12, Sh5:6). (B) Schematic description of the cell morphology, cell surface markers and heme availability during terminal erythroid differentiation. The representative pictures are of erythroid progenitors from the erythroid culture, stained with DAB-Giemsa. (C) Representative plots and (D) quantification of flow cytometry analysis of GPA (top) and CD49d/Band3 within GPA+ (bottom) on day 10, 14, 18 and 21 of erythroid in vitro differentiation (n = SCR:4, Sh3:12, Sh5:6). (E) Representative pictures at 40× magnification and (F) quantification of progenitors from cytospins stained with DAB-Giemsa (n = 3–4). Quantification was not possible on day 10 as GPA+ and GPA− progenitors cannot be differentiated. Data is presented as mean ± SEM (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
we recently showed that down-regulation of pgc1β in response to pRb deletion correlated with decreased expression of genes involved in mitochondrial function, as well as heme synthesis and iron transport in mouse21, and compound deletion of the related Pgc1α and Pgc1β genes in mouse has indicated that PGC1 coactivators might be able to affect globin gene transcription during fetal development26. Furthermore, mitochondrial clearance has been shown to be important for human terminal erythroid differentiation, with mitochondrial retention due to deregulated mitophagy resulting in perturbed enucleation14,15. To investigate mitochondrial effects of reduced PGC1β expression during human erythroid differentiation, we analyzed the expression of key genes involved in oxidative phosphorylation (OXPHOS) in BM derived erythroid progenitors on day 18 (Fig. 4A–C) and CB derived erythroid progenitors on day 16 (Fig. 4D–F). In BM, decreased PGC1β expression resulted in decreased expression of COX7B (Cytochrome C Oxidase, respiratory electron transport34), SDHB (CII: respiratory electron transport35), NDUFA1 (CI: respiratory electron transport36) and ATP5S (ATP synthesis37) in polychromatic erythroblasts (Fig. 4B). In contrast, the expression of COX7B and SDHB were increased while
**A**

SCRS shRNA3

**B**

![Graph showing CD49d+ Band3 expression](image)

**C**

![Graph showing Rel. Exp. in CD49d+ Band3-](image)

**D**

![Graph showing SCR shRNA3](image)

**E**

![Graph showing SCR shRNA3](image)

**F**

![Graph showing SCR shRNA3](image)

**G**

CD49d+ Band3-

**H**

![Graph showing SCR shRNA3](image)

**I**

![Graph showing SCR shRNA3](image)

**J**

![Graph showing SCR shRNA3](image)

**K**

![Graph showing SCR shRNA3](image)

**L**

![Graph showing SCR shRNA3](image)

**M**

![Graph showing SCR shRNA3](image)

**N**

SCR shRNA3

**O**

![Graph showing SCR shRNA3](image)

**P**

![Graph showing SCR shRNA3](image)

**Q**

![Graph showing SCR shRNA3](image)

**R**

![Graph showing SCR shRNA3](image)

**S**

![Graph showing SCR shRNA3](image)
We next sought to understand the involvement of PGC\textsubscript{1}\textbeta in regulation of hemoglobin composition and iron transport, biological processes taking place in the mitochondria that are fundamental for proper red blood cell function. Transcriptional analysis of BM-derived erythroid progenitors on day 18 revealed that the expression of TMEM14C (transporter of protoporphyrinogen\textsuperscript{38}) was increased, ALAS2 (the rate-limiting enzyme in heme transport, biological processes taking place in the mitochondria that are fundamental for proper red blood cell function).
PGC1β knock-down results in disturbed cell cycle exit and smaller reticulocytes. Activation of PPAR signaling has been found to be involved in induction of cell cycle arrest in adipocytes\(^{41}\) and inhibition of cell growth in human colorectal cancer cell lines\(^{42}\). In addition, we recently demonstrated in mouse that down-regulation of PGC1β in response to pRb deletion correlated with enhanced cycling and increased expression of cell cycle genes in erythroid progenitors\(^{21}\). Importantly, overexpression of Pgc1β could normalize the deregulated expression of cell cycle genes induced by pRb deficiency\(^{21}\). To further study the direct role of PGC1β in cell cycle regulation in human erythropoiesis, polychromatic erythroblasts from day 18 of culture were stained with DAPI and analyzed for cell cycle status using FACS (Fig. 5A). Since erythroid cells are sensitive to permeabilization and fixation, the polychromatic erythroblasts were sorted prior to fixation and staining. In accordance with our previous results in mouse\(^{21}\), decreased expression of PGC1β resulted in fewer polychromatic erythroblasts in G1-phase and a 1.5- and twofold increase in cells remaining in S-phase for sh3 and sh5 respectively compared to control (Fig. 5A). Transcriptional analysis on day 18 of genes involved in G1 to S progression revealed that, while the expression of these genes was largely unchanged polychromatic erythroblasts (Fig. 5B), the expression of E2F7 and E2F8 (repression of G1/S-regulated genes\(^{43}\), CDK2 (G1/S transition\(^{44}\), and CCNE1 (regulator of CDK2\(^{45}\)) were greatly upregulated in the slightly more mature orthochromatic erythroblasts (Fig. 5C). The same cell cycle related genes were also up-regulated in CB derived erythroblasts on day 16 already at the polychromatic erythroblast stage (Fig. 5D), demonstrating that reduced levels of PGC1β affects cell cycle regulation in both BM and CB erythropoiesis, in spite of known differences in cell cycle status between these hematopoietic tissues\(^{46}\).

It has been shown that erythroid precursors that undergo fewer cell divisions result in larger erythrocytes\(^{47}\). To investigate if enhanced cycling resulted in reduced cell size, we quantified the size of the orthochromatic erythroblasts/Reticulocytes (CD49d− Band3+) on day 21 using Forward Scatter Area (FSC-A) and flow cytometry. Results clearly demonstrated that reduced expression of PGC1β resulted in a 13.6% (sh3) and 8.4% (sh5) decrease in median FSC-A compared to cells transduced with control vector (Fig. 5D). Similarly, quantification of the 2D area of reticulocytes from cytoflex images at day 21 of culture using ImageJ\(^{48,49}\) demonstrated a 10% decrease in cell area using the more efficient sh3, while there was no significant difference in reticulocyte size observed using sh5 (Fig. 5E). Taken together, our results demonstrate that decreased expression of PGC1β results in perturbed human erythroid differentiation, reduced mitochondrial clearance, disrupted hemoglobin production, inability to properly exit cell cycle, and a consequent reduced cell size of reticulocytes (Fig. 6).

Discussion

Multiple pathways involved in cell cycle regulation, organelle clearance, apoptosis and iron homeostasis are crucial for functional erythropoiesis\(^{50–53}\). A central player for several of these pathways is the mitochondria. However, mechanisms regulating mitochondrial function during erythropoiesis remains elusive. Here we demonstrate that decreased expression of PGC1β a critical coactivator of mitochondrial biogenesis, results in perturbed formation of early erythroid progenitors and delayed human erythroid differentiation, reduced reticulocyte size, disturbed cell cycle regulation and deregulated hemoglobinization. Knock-down of PGC1β expression resulted in a substantial and similar phenotype with both short hairpins used, in spite of their different and relatively low knock-down efficiencies (sh3: 50%, sh5: 20%), demonstrating the importance of unperturbed levels of PGC1β for both early and terminal erythroid development. shRNA mediated gene silencing can either degrade mRNA or inhibit protein translation. The weaker effect on mRNA transcription, but stronger reduction at the protein level detected using sh5, could hence potentially be due to sh5 exerting its effect mainly through stronger inhibition of protein translation.
PGC1α has been shown to have a compensatory effect in other tissues in Pgc1β KO mice. We therefore investigated if reduced expression of PGC1β resulted in a compensatory increase in PGC1α in the human setting. PGC1α expression, which was undetectable in wildtype ortho/poly chromatic erythroblasts, was however not upregulated in response to reduced levels of PGC1β (data not shown), ruling out compensatory mechanisms between the two homologs in the erythroid compartment.

Being a coactivator of mitochondrial biogenesis, it could be expected that reduced expression of PGC1β would result in decreased expression of OXPHOS related genes and proteins. In contrast, mitochondrial biomass was increased in all BM derived erythroblast populations on day 14 as measured by MTDR. This is likely due to disrupted mitophagy. During terminal erythroid differentiation mitochondria undergo mitophagy leading to decreased MTDR intensity, which is also evident by our data, demonstrating a stepwise reduction of MF in maturing erythroblasts in the control cells (Fig. S4B, SCR black bars). This is also in agreement with our data showing that the mitochondrial housekeeping protein TOM20 is present in polychromatic erythroblasts (Fig. 4G,H), but no longer detectable in orthochromatic erythroblasts (Fig. S4A). That PGC1β likely plays a functional role in mitochondrial clearance was further strengthened by that knock-down of PGC1β resulted in

---

**Figure 5.** PGC1β knock-down results in perturbed cell cycle exit and smaller reticulocytes. (A) Representative plots indicating populations analyzed (SCR, left) and cell cycle profile (middle), and quantification (right) of the cell cycle status on d18 within bone marrow derived polychromatic erythroblast (CD49d⁺ Band3⁻), using flow cytometry and DAPI (n = SCR:4, Sh3:12, Sh5:6). (B, C) Analysis of expression relative to GAPDH on day 18 of cell cycle related genes involved in G1 to S phase progression in (B) polychromatic erythroblasts (CD49d⁺ Band⁻), and (C) orthochromatic erythroblasts (CD49d⁺ Band⁺) using RT-qPCR (n = SCR:4, Sh3:12, Sh5:6). (D) Representative plot indicating populations analyzed (SCR, left) and quantification (right) of cell size using flow cytometry and FSC-A within orthochromatic erythroblasts (CD49d⁻ Band⁺) on day 21 at the final stage in terminal differentiation. (E) 2D cell area quantification of enucleated cells (day 21) stained with DAB-Giemsa, using cytospin microscopy images and ImageJ software, (n = SCR:4, Sh3:12, Sh5:6). Data is presented as mean ± SEM (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
has been attributed to heterozygous deletion of RPS14. It is unlikely that the full disease phenotype is caused by a single gene out of the 40 coding genes included in the commonly deleted region of chromosome 5 of the del(5q) subtype of MDS. Patients with del(5q) MDS exhibit a similar inefficient erythropoiesis to that described here, indicating that PGC1β deficiency be due to the retention of mitochondria, or a cell intrinsic attempt to compensate for deregulated heme-regulation at earlier stages of differentiation, as seen in BM.

Erythropoiesis is intimately coupled to cell cycle regulation, and erythroblasts undergo initial self-renewal divisions, followed by a series of quick divisions during terminal differentiation to give rise to the immense amounts of mature RBCs each day. In addition to its more established role as regulator of mitochondrial biogenesis and energy metabolism, PGC1β has been implicated in cell cycle regulation of cancer cells. Furthermore, we recently showed that enhanced Pgc1β expression alone was enough to normalize the disrupted expression of cell cycle related genes in pRb-deficient murine erythroblasts. Here we show that multiple genes involved in G1 to S progression were greatly increased in response to PGC1β knock-down in both BM and CB derived erythroblasts, demonstrating a direct involvement of PGC1β in cell cycle regulation. While the total expression of pRB, a G1-S master regulator, was unchanged, CDK2 that targets pRB for phosphorylation was significantly increased. Hence, hyper-phosphorylation of pRB by CDK2 could potentially contribute to increased cell cycle progression in PGC1β-deficient cells. Furthermore, in line with a previous publication showing that erythroid precursors that undergo fewer cell divisions result in larger reticulocytes, we here demonstrate that increased cell cycle progression results in smaller reticulocytes.

The disrupted terminal erythroid differentiation with accumulations of polychromatic and orthochromatic erythroblasts that we see in response to decreased levels of PGC1β is reminiscent of the impaired terminal erythroid differentiation seen in MDS. The majority of MDS patients are transfusion dependent, which negatively affect their quality of life, clinical outcome and correlates with increased risk of leukemic transformations. A high frequency of acquired mutations in mitochondrial DNA has been reported in MDS patients. For example, subtypes of MDS with somatic SF3B1 mutations are associated with downregulation of core mitochondrial pathways. This includes deregulation of genes important for iron and heme homeostasis, suggesting that these biological processes could contribute to the disease phenotype. Notably, PGC1β is located within the commonly deleted region of chromosome 5 of the del(5q) subtype of MDS. While the pathogenesis of del(5q) MDS has been attributed to heterozygous deletion of RPS14, it is unlikely that the full disease phenotype is caused by the loss of a single gene out of the 40 coding genes included in the commonly deleted region. Patients with del(5q) MDS exhibit a similar inefficient erythropoiesis to that described here, indicating that PGC1β deficiency potentially also contributes to the disease phenotype. In addition, reduced PGC1β expression result in disrupted heme and globin coordination, which is also reported in del(5q) MDS. Furthermore, Lenalidomide, which is...
used to treat del(5q) MDS patients⁶⁹, has been shown to also affect mitochondrial homeostasis⁷⁰. However, further studies are needed to determine if disturbed PPAR-signaling is involved in MDS-related anemia pathogenesis.

**Materials and methods**

**Human BM cells.** Human bone marrow (BM) cells were supplied by Lonza or collected at the Hematology Department, University of Lund, Sweden. Informed consent was obtained from all participants. All work on BM samples was done according to ethical guidelines approved by the Institutional Review Board of the University of Lund and in accordance with the Declaration of Helsinki.

**Vector design and transduction.** Bacterial glycerol stocks with shPGC1β inserts from MISSION® sh3: TRCN00000008600 and sh5: TRCN000429958 clones (Sigma Aldrich, St. Louis, MO, USA) or scrambled for control, as described in Supplemental Table 1, were cloned into pLKO lentiviral vector with eGFP reporter gene using NdeI and BamHI restriction enzymes. Control digestions on plasmid were done with NdeI and BamHI prior to sequencing. Cloned plasmids were sent with U6 FWD primer to Eurofins Scientific (Luxembourg) for plasmid sequence confirmation.

Approximately 100,000 CD34+ cells were transduced with shPGC1β lentiviral vectors or scramble control vector in phase I medium (see below) supplemented with 0.4 µg/mL Protamine sulphate. Upon validation of different shPGC1β vectors, variance was observed in knock-down efficiency between transduction replicates of the same vector and donor. To ensure sufficient knock-down efficiency for all donor samples, more transductions were performed with the shPGC1β vectors as compared to the control Scramble vector. This was done to avoid losing biological transductions to inefficient transductions Transduced (GFP+) CD34+ (APC-eFluor780, Thermo Fisher Scientific, Waltham, MA, USA) cells were sorted into RLT buffer (1% β-mercaptoethanol) 48 h after transduction for analysis of PGC1β knockdown efficiency.

**Erythroid culture.** Transduced CD34+ bone marrow cells (Lonza, Basel, Switzerland) were sorted 48 h post transduction on Aria III based on GFP and CD34 (4H-11, APC-eFluor780, Thermo Fisher Scientific) expression and cultured in a 3-phase erythroid culturing system; 5 days in phase 1 medium, consisting of SFEM supplemented with 1% penicillin streptomycin, 50 ng/ml SCF, 10 ng/ml IL-3, 50 ng/ml TPO and 100 nM Dexamethasone, followed by 7 days in phase 2 medium (SFEM with 1% penicillin streptomycin, 50 ng/ml SCF, 10 ng/ml IL-3, 50 ng/ml TPO and 2U/ml EPO and 100 nM Dexamethasone) for differentiation of erythroid committed progenitors. On Day 14 the medium was switched to phase 3 medium (SFEM with 1% penicillin streptomycin, 30% heat inactivated FBS and 3U/ml EPO) for terminal erythroid differentiation. Cells were collected on day 10, 14, 18 and 21 (BM) and day 10, 14 and 16 (CB) for morphologic and flow cytometric analysis. Cells collected on day 18 for BM and day 16 for CB were also sorted for RT-qPCR, Western analysis (CB) and cell cycle analysis (BM).

**Erythroid colony formation assay.** 1000 transduced CD34+ cells were plated in MethoCult™ (H4230, Stemcell Technologies) supplemented with 20 ng/ml SCF, 10 ng/ml IL3, 50 ng/ml GM-CSF, 3U/ml EPO, incubated at 37 °C and 5% CO₂ and scored for CFU-E colonies after 14 days.

**Morphologic scoring of diaminobenzidine (DAB) stained BM derived erythroid progenitors.** Approximately 10,000−15,000 cells were spun down on cytopsins slides and fixed with methanol at −20 °C for 2 min. The slides were air-dried and stained with Diaminobenzidine hydrochloride (DAB) solution (10 mg/ml in PBS, Sigma Aldrich) including freshly added H₂O₂ (3 ppm, Sigma Aldrich). DAB solution was applied on the slides with the help of a PAP pen to cover all cells. The slides were washed with DHB2, stained with Giemsa (1:20 dilution in distilled water) for 15 min, wash with DHB2, and air-dried. 300 cells per transduction were visually scored into five different developmental stages based on known morphologic characteristics including presence and size of nucleus, hemoglobin content and general cell size, using an Olympus BX43 microscope (Olympus Corporation, Tokyo, Japan) and 40 × magnification. Apoptotic cell displaying blebbing and or fragmentation were excluded.

Cell area and hemoglobin stain intensity was scored using ImageJ⁴⁸,⁴⁹ (v1.153c). For quantification of cell size, images were converted to grayscale by changing type to 8-bit and converted to binary format. Cell area was quantified using ‘Analyze particles’ with a threshold of 50–150 µm². For quantification of hemoglobin content, reticulocytes were marked with selection tool, followed by subtraction of noise, grayscale conversion and inversion of image. Reticulocytes were then analyzed for DAB color intensity by measuring integrated density. For more detail see Supplemental Methods.

**Flow cytometric analysis.** Cultured transduced cells were collected on days 10, 14, 18, 21 (BM) and days 10, 14, 16 (CB) for FACS analysis. The cells were washed with PBS (GE Healthcare Life Sciences) with 2% FCS (GE Healthcare Life Sciences) and stained with the cell surface markers GPA (GA-R2, BV421, BD), CD49d (9F10, PeCy7, BioLegend) and Band3 (Bric 6, PE/APC, BGRIL Research Products). MitoTracker Deep Red (50 nM, Thermo Fisher Scientific), TMRE (100 nM, Thermo Fisher Scientific) and MitoSox (250 nM, Thermo Fisher Scientific) was included to measure mitochondrial biomass, membrane potential and ROS production respectively. Nucleic Acid Stain Syto62 (25 nM) was included to assess enucleation. 7-Aminoactinomycin D (7-AAD, Sigma Aldrich) was used to exclude dead cells. Samples were analyzed and sorted on FACS Aria III, FACS Aria II and LSR Fortessa.
Cell cycle analysis. Since erythroid cells are sensitive to permeabilization and fixation, 200,000–400,000 polychromatophilic erythroblasts were sorted based on their GPA, CD49d and Band3 expression prior to fixation. Cell pellets were fixed with ice cold 70% Ethanol in PBS (GE Healthcare Life Sciences) while vortexing and incubated at −20 °C overnight. Fixed cells were washed with PBS and stained with DAPI staining buffer (0.1% TritonX100 (Sigma Aldrich), 0.1% Sodium citrate (Sigma Aldrich)) for 30 min at 37 °C. DAPI intensity was analyzed individually in the sorted erythroid progenitor populations on LSR Fortessa (Becton Dickinson).

Gene expression. 5000–20,000 polychromatophilic (CD49d+, Band3−) and orthochromat (CD49d+, Band3+) erythroid progenitors were sorted into RLT buffer (1% β-mercaptoethanol) and snap frozen. RNA was purified using RNaseq mini kit according to instructions (Qiagen) and cDNA was prepared using SuperScript IV reverse transcriptase (Thermo Fisher Scientific). RT-qPCR assays were performed according to the TaqMan Gene expression master mix protocol and pre-designed probe-based primers (Supplemental Table 2) (Integrated DNA Technologies, Coralville, IA USA and Thermo Fisher Scientific).

SDS-PAGE and immunoblotting. Whole cell lysates of transduced cord blood derived cells on day7 were used for analysis of knock-down efficiency, and GPA+, CD49d+/Band3− and CD49d+/Band3+ populations were sorted on day 16 for analysis of OXHPOS and cell cycle proteins. Sorted cells were prepared with RIPA lysis and extraction buffer (Fisher scientific). Protein concentration of lysates were quantified with Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific) and proteins were separated using NuPAGE® 4–12% Bis–Tris gels. Proteins were transferred to nitrocellulose membrane using Trans-Blot Turbo Transfer System (BioRad, Hercules, CA, USA). Immunoblotting was done with following antibodies and dilutions overnight at 4 °C: Rabbit Anti-PGC1 beta Ab (ab176328, 1:1000, Abcam, Cambridge UK), Rabbit Anti-NDUFA1 Ab (ab176563, 1:1000, Abcam), Mouse Anti-TOM20 Ab (sc-17764, 1:1000, Santa Cruz Biotechnology, Dallas, TX, USA), Mouse Anti-ALAS-E Ab (sc-166739, 1:1000, Santa Cruz Biotechnology), Mouse Anti-Ferrochelatase Ab (sc-377377, 1:1000, Santa Cruz Biotechnology) Rabbit Anti-ATP5S Ab (PA5-101443, 1:1000, Fisher Scientific), Mouse Anti-Actin (Ab-5, 1:1000, Biosciences), HRP coupled anti-rabbit IgG (NA9340-1ML, 1:5000, Cytiva), HRP coupled anti-mouse IgG (NA9310-1ML, 1:5000, Cytiva). Proteins of interest were exposed using Amersham ECL Prime Western Blotting Detection Reagent (Cytiva, Marlborough, MA, USA). Images were acquired with ChemiDoc™ Imaging Systems (Bio-Rad) and bands intensity were quantified with Image Lab software (v6.0, Bio-Rad).

Statistics. Statistical analysis was done using GraphPad Prism 8.00 or 9.00 (GraphPad Software, San Diego, CA USA). Significance was analyzed with 2way ANOVA test, corrected for multiple comparisons, using Sidak’s or two-stage step-up method of Benjamini, Krieger and Yekutieli (False discovery rate), if not stated otherwise. Students paired t-test was used for analyzing RT-qPCR, Enucleation, DAB intensity and Cell size analyses, when only comparing two groups.

References

1. Palis, J. Primitive and definitive erythropoiesis in mammals. Front. Physiol. 5, 3 (2014).
2. Hattangadi, S. M., Wong, P., Zhang, L., Flygare, J. & Lodish, H. F. From stem cell to red cell: Regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 118(24), 6258–6268 (2011).
3. Singbrant, S. et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 117(21), 5631–5642 (2011).
4. Koury, M. J. & Bondurant, M. C. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J. Cell Physiol. 137(1), 65–74 (1988).
5. Kelley, L. L. et al. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol. Cell Biol. 14(6), 4183–4192 (1994).
6. An, X., Schulz, V. P., Mohandas, N. & Gallagher, P. G. Human and murine erythropoiesis. Curr. Opin. Hematol. 22(3), 206–211 (2015).
7. Chen, K. et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl. Acad. Sci. USA 106(41), 17413–17418 (2009).
8. Liu, X. et al. Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation. Nat. Cell Biol. 19(6), 626–638 (2017).
9. Fontenay, M., Cathelin, S., Amiot, M., Gyan, E. & Solary, E. Mitochondria in hematopoiesis and hematological diseases. Oncogene 25(34), 4757–4767 (2006).
10. Zhang, S. et al. HRI coordinates translation necessary for protein homeostasis and mitochondrial function in erythropoiesis. Elife 8, 1–10 (2019).
11. Jensen, E. L. et al. Copper deficiency-induced anemia is caused by a mitochondrial metabolic reprogramming in erythropoietic cells. Metallomics 11(2), 282–290 (2019).
12. Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365(15), 1384–1395 (2011).
13. Gonzalez-Menendez, P. et al. An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism. Cell Rep. 34(5), 108723 (2021).
14. Moras, M. et al. Human erythroid differentiation requires VDAC1-mediated mitochondrial clearance. Haematologica 106(4), 1000–20,000 polychromatophilic (Cd49d+, Band3−) and orthochromat (Cd49d+, Band3+) erythroid progenitors were sorted into RLT buffer (1% β-mercaptoethanol) and snap frozen. RNA was purified using RNAeasy mini kit according to instructions (Qiagen) and cDNA was prepared using SuperScript IV reverse transcriptase (Thermo Fisher Scientific). RT-qPCR assays were performed according to the TaqMan Gene expression master mix protocol and pre-designed probe-based primers (Supplemental Table 2) (Integrated DNA Technologies, Coralville, IA USA and Thermo Fisher Scientific).
16. Finck, B. N. & Kelly, D. P. PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. *J. Clin. Invest.* **116**(3), 613–622 (2006).
17. Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* **92**(6), 829–839 (1998).
18. Nicholls, D., Cunningham, S. & Wiesinger, H. Mechanisms of thermogenesis in brown adipose tissue. *Biochem. Soc. Trans.* **14**(2), 223–225 (1986).
19. Lin, J., Puigserver, P., Donovan, J., Tarr, P. & Spiegelman, B. M. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. *J. Biol. Chem.* **277**(3), 1645–1648 (2002).
20. Kressler, D., Schreiber, S. N., Knutti, D. & Kralli, A. The PGC-1–related protein PERC is a selective coactivator of estrogen receptor alpha. *J. Biol. Chem.* **277**(16), 13918–13925 (2002).
21. Sen, T. et al. Enhancing mitochondrial function in vivo rescues MDS-like anemia induced by Pfb deficiency. *Exp. Hematol.* **38**, 28–41 (2010).
22. Lehman, J. I. et al. Peroxisome proliferator-activated receptor gamma coactivator–1 promotes cardiac mitochondrial biogenesis. *I. Clin. Invest.* **106**(7), 847–856 (2000).
23. St-Pierre, J. et al. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. *J. Biol. Chem.* **278**(29), 26597–26603 (2003).
24. Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* **98**(1), 115–124 (1999).
25. Spiegelman, B. M., Puigserver, P. & Wu, Z. Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. *Cell Metab.* **1**(5), 305–316 (2000).
26. Cui, S. et al. Severe impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. *Blood Adv.* **2**(12), 1393–1402 (2018).
27. Giagounidis, A. A., Germing, U. & Aul, C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. *Clin. Cancer Res.* **12**(1), 5–10 (2006).
28. Wulfert, M. et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. *Exp. Hematol.* **36**(5), 577–586 (2008).
29. Nikpour, M. et al. Gene expression profiling of erythroblasts from refractory anemia with ring sideroblasts (RARS) and effects of G-CSF. *Br. J. Haematol.* **149**(6), 844–854 (2010).
30. Conte, S. et al. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. *Br. J. Haematol.* **171**(4), 478–490 (2015).
31. Hu, J. et al. Isolation and functional characterization of human erythroblasts at distinct stages: Implications for understanding of normal and disorders of erythropoiesis in vivo. *Blood* **121**(16), 3246–3253 (2013).
32. Yan, H. et al. Developmental differences between neonatal and adult human erythropoiesis. *Am. J. Hematol.* **93**(4), 494–503 (2018).
33. Fontanesi, F. et al. The transcription factor NAPI1 is required for erythroid differentiation and self-renewal in erythroid progenitors. *Am. J. Physiol. Cell Physiol.* **291**(6), C1129–C1147 (2006).
34. Bezawork-Geleta, A., Rohlena, J., Dong, L., Pacak, K. & Neuzil, J. Mitochondrial complex II: At the crossroads. *Trends Biochem. Sci.* **32**(4), 312–325 (2017).
35. Au, H. C., Seo, B. B., Matsuno-Yagi, A., Yagi, T. & Scheller, I. E. The NDUFA1 gene product (MWFE protein) is essential for activity of complex I in mammalian mitochondria. *Proc. Natl. Acad. Sci. USA.* **96**(8), 4354–4359 (1999).
36. Belogrudov, G. I. & Hatle, Y. Factor B and the mitochondrial ATP synthase complex. *J. Biol. Chem.* **277**(8), 6097–6103 (2002).
37. Yien, Y. Y. et al. TMEM14C is required for erythroid mitochondrial heme metabolism. *Blood* **124**(10), 4294–4304 (2014).
38. De Brouwer, N., Thompson, E. G. & Neuzil, J. Mitochondrial heme biosynthesis. *Biochim. Biophys. Acta.* **1763**(7), 723–736 (2006).
39. Maio, N., Kim, K. S., Holmes-Hampton, G., Singh, A. & Rouault, T. A. Dimercerohemelate bridges ABCB7 and ABCB10 homodimers in an architecturally defined molecular complex required for heme biosynthesis. *Haematologica* **104**(9), 1756–1767 (2019).
40. Hansen, J. B. et al. Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinolblastoma protein in adipocyte differentiation. *J. Biol. Chem.* **274**(24), 2386–2393 (1999).
41. Lin, M. S. et al. Development of erythroid differentiation in human erythroblasts. *Blood* **124**(10), 4294–4304 (2014).
42. Li, J. et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. *Dev. Cell.* **14**(1), 62–75 (2008).
43. Berthet, C. et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. *Dev. Cell.* **10**(5), 563–573 (2006).
44. Geng, Y. et al. Cyclin E ablation in the mouse. *Cell* **114**(4), 431–443 (2003).
45. De Bruyn, C., Delforge, A., Lagneaux, L. & Bron, D. Characterization of CD34+ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation. *Bone Marrow Transplant.* **25**(4), 377–383 (2000).
46. Sankaran, V. G. et al. Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number. *Genes Dev.* **26**(18), 2057–2087 (2012).
47. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. *Nat. Methods.* **9**(7), 676–682 (2012).
48. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods.* **9**(7), 671–675 (2012).
49. Gnanapragasam, M. N. et al. EKLF/KLF1 regulated cell cycle exit is essential for erythroblast enucleation. *Blood* **128**(12), 1631–1641 (2016).
50. Moras, M., Lefevre, S. D. & Ostuni, M. A. From erythroblasts to mature red blood cells: Organelle clearance in mammals. *Front. Physiol.* **8**, 1076 (2017).
51. Testa, U. Apoptotic mechanisms in the control of erythropoiesis. *Leukemia* **18**(7), 1176–1199 (2004).
52. Ganz, T. & Nemeth, E. Iron metabolism: Interactions with normal and disordered erythropoiesis. *Cold Spring Harb. Perspect Med.* **2**(5), 011668 (2012).
53. Sonoda, J., Mehl, I. R., Chong, L. W., Nofsinger, R. R. & Evans, R. M. PGC-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. *Proc. Natl. Acad. Sci. USA.* **104**(12), 5223–5228 (2007).
54. Mauro-Lisciano, M. et al. New method to assess mitophagy flux by flow cytometry. *Autophagy* **11**(5), 833–843 (2015).
55. Liang, R. et al. Mitochondrial localization and moderated activity are key to murine erythropoiesis. *Blood* **150**(5), 2490–2504 (2021).
56. von Lindern, M. et al. Leukemic transformation of normal murine erythroid progenitors: V- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis. *Oncogene* **20**(28), 3651–3664 (2001).
57. Pop, R. et al. A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase progression. *PLoS Biol.* **8**(9), e1000484 (2010).
58. Classon, M. & Harlow, E. The retinolblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer.* **12**(1), 910–912 (2012).
60. Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P. & Wimalasena, J. Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin D1–Cdk4 function. *Mol. Cell Biol.* 21(3), 794–810 (2001).

61. Ryblom, H., Hast, R., Hellstrom-Lindberg, E., Winterling, J. & Johansson, E. Self perception of symptoms of anaemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes. *Eur. J. Oncol. Nurs.* 19(2), 99–106 (2015).

62. Hellstrom-Lindberg, E. & van de Loosdrecht, A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. *Best Pract Res Clin Haematol.* 26(4), 401–410 (2013).

63. Kao, J. M., McMillan, A. & Greenberg, P. L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. *Am. J. Hematol.* 83(10), 765–770 (2008).

64. Balducci, L. Transfusion independence in patients with myelodysplastic syndromes: Impact on outcomes and quality of life. *Cancer* 106(10), 2087–2094 (2006).

65. Malcovati, L. *et al.* SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. *Blood* 126(2), 233–241 (2015).

66. Jadersten, M. & Karsan, A. Clonal evolution in myelodysplastic syndromes with isolated del(5q): The importance of genetic monitoring. *Haematologica* 96(2), 177–180 (2011).

67. Schneider, R. K. *et al.* Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. *Nat. Med.* 22(3), 288–297 (2016).

68. Yang, Z. *et al.* Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome. *Sci. Transl. Med.* 8(338), 338–367 (2016).

69. Talati, C., Sallman, D. & List, A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. *Semin. Hematol.* 54(3), 159–166 (2017).

70. Pearson, G. & Soleimanpour, S. A. A ubiquitin-dependent mitophagy complex maintains mitochondrial function and insulin secretion in beta cells. *Autophagy* 14(7), 1160–1161 (2018).

Acknowledgements
We are grateful to project students Kristina Munke and Mathilda Wessman for laboratory assistance during initial pilot experiments of this study, and to Dr. Abdul Ghani Alattar and Dr. Carl Walkley for intellectual input. This research was supported by the Swedish Society for Medical Research (fellowship SS), the Crafoordska Foundation (Grant No. 20170902), the Åke Wiberg Foundation (Grant No. M17/0252), the Clas Groschinsky’s Memory Foundation (Grant No. M1789), the Gunnar Nilsson Cancer Foundation (Grant No. GN-2017-38), the Royal Physiographic Society of Lund, and the Harald & Greta Jeansson Foundation (SS).

Author contributions
T.S. and S.S. conceived the study, T.S. and S.S. designed experiments, T.S. and J.C. performed experiments and T.S. and S.S. analyzed data, T.S. and S.S. wrote the manuscript, and all authors have commented on the final draft.

Funding
Open access funding provided by Lund University.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-96585-0.

Correspondence and requests for materials should be addressed to S.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021